Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Zongertinib Tablets in Healthy Participants
NCT07789028Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zongertinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0-72h up to 4 days and Maximum measured concentration of the analyte in plasma up to 4 days. Started Sep 2026; status: recruiting.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07789028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789028.